메뉴 건너뛰기




Volumn 45, Issue 5, 2017, Pages 380-388

Clinical Trial of Vadadustat in Patients with Anemia Secondary to Stage 3 or 4 Chronic Kidney Disease

Author keywords

Anemia; Chronic kidney disease; Clinical trials; Erythropoietin; Kidney disease

Indexed keywords

FERRITIN; HEMOGLOBIN; HEPCIDIN; IRON; PLACEBO; VADADUSTAT; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CHOLESTEROL; ERYTHROPOIETIN; GLYCINE; HYPOXIA INDUCIBLE FACTOR PROLINE DIOXYGENASE; PICOLINIC ACID DERIVATIVE; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

EID: 85016641947     PISSN: 02508095     EISSN: 14219670     Source Type: Journal    
DOI: 10.1159/000464476     Document Type: Article
Times cited : (111)

References (35)
  • 1
    • 1342343893 scopus 로고    scopus 로고
    • Impact of epoetin alfa on clinical end points in patients with chronic renal failure: A meta-analysis
    • Jones M, Ibels L, Schenkel B, Zagari M: Impact of epoetin alfa on clinical end points in patients with chronic renal failure: a meta-analysis. Kidney Int 2004; 65: 757-767.
    • (2004) Kidney Int , vol.65 , pp. 757-767
    • Jones, M.1    Ibels, L.2    Schenkel, B.3    Zagari, M.4
  • 4
    • 0032572913 scopus 로고    scopus 로고
    • The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin
    • Besarab A, Bolton WK, Browne JK, Egrie JC, Nissenson AR, Okamoto DM, Schwab SJ, Goodkin DA: The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 1998; 339: 584-590.
    • (1998) N Engl J Med , vol.339 , pp. 584-590
    • Besarab, A.1    Bolton, W.K.2    Browne, J.K.3    Egrie, J.C.4    Nissenson, A.R.5    Okamoto, D.M.6    Schwab, S.J.7    Goodkin, D.A.8
  • 7
    • 84879836673 scopus 로고    scopus 로고
    • Kidney Disease: Improving Global Outcomes guidelines on anaemia management in chronic kidney disease: A European renal best practice position statement
    • ERA-EDTA ERBP Advisory Board
    • Locatelli F, Barany P, Covic A, De Francisco A, Del Vecchio L, Goldsmith D, Horl W, London G, Vanholder R, Van Biesen W; ERA-EDTA ERBP Advisory Board: Kidney Disease: Improving Global Outcomes guidelines on anaemia management in chronic kidney disease: a European renal best practice position statement. Nephrol Dial Transplant 2013; 28: 1346-1359.
    • (2013) Nephrol Dial Transplant , vol.28 , pp. 1346-1359
    • Locatelli, F.1    Barany, P.2    Covic, A.3    De Francisco, A.4    Del Vecchio, L.5    Goldsmith, D.6    Horl, W.7    London, G.8    Vanholder, R.9    Van Biesen, W.10
  • 8
    • 84884333035 scopus 로고    scopus 로고
    • KDIGO clinical practice guideline for anemia in chronic kidney disease
    • Kidney Disease: Improving Global Outcomes (KDIGO) Anemia Work Group: KDIGO clinical practice guideline for anemia in chronic kidney disease. Kidney Int Suppl 2012; 2: 279-335.
    • (2012) Kidney Int Suppl , vol.2 , pp. 279-335
  • 13
    • 38449094145 scopus 로고    scopus 로고
    • Mechanism of increased mortality risk with erythropoietin treatment to higher hemoglobin targets
    • Fishbane S, Besarab A: Mechanism of increased mortality risk with erythropoietin treatment to higher hemoglobin targets. Clin J Am Soc Nephrol 2007; 2: 1274-1282.
    • (2007) Clin J Am Soc Nephrol , vol.2 , pp. 1274-1282
    • Fishbane, S.1    Besarab, A.2
  • 14
    • 85016741044 scopus 로고    scopus 로고
    • The dawning of a new day in CKD anemia care?
    • Lenihan CR, Winkelmayer WC: The dawning of a new day in CKD anemia care? J Am Soc Nephrol 2016; 27: 968-970.
    • (2016) J Am Soc Nephrol , vol.27 , pp. 968-970
    • Lenihan, C.R.1    Winkelmayer, W.C.2
  • 15
    • 85047682984 scopus 로고    scopus 로고
    • Regulation of oxygen homeostasis by hypoxia-inducible factor 1
    • Semenza GL: Regulation of oxygen homeostasis by hypoxia-inducible factor 1. Physiology (Bethesda) 2009; 24: 97-106.
    • (2009) Physiology (Bethesda) , vol.24 , pp. 97-106
    • Semenza, G.L.1
  • 16
    • 0037362890 scopus 로고    scopus 로고
    • HIF hydroxylation and the mammalian oxygen-sensing pathway
    • Safran M, Kaelin WG Jr: HIF hydroxylation and the mammalian oxygen-sensing pathway. J Clin Invest 2003; 111: 779-783.
    • (2003) J Clin Invest , vol.111 , pp. 779-783
    • Safran, M.1    Kaelin, W.G.2
  • 17
    • 85019806112 scopus 로고    scopus 로고
    • Dose exposure relationship of vadadustat is independent of the level of renal function
    • Buch A, Maroni BJ, Hartman CS: Dose exposure relationship of vadadustat is independent of the level of renal function. J Am Soc Nephrol 2015; 26:#SA-PO537.
    • (2015) J Am Soc Nephrol , vol.26 , pp. SA-PO537
    • Buch, A.1    Maroni, B.J.2    Hartman, C.S.3
  • 18
    • 84933181755 scopus 로고    scopus 로고
    • AKB-6548, a new hypoxia-inducible factor prolyl hydroxylase inhibitor increases hemoglobin while decreasing ferritin in a 28-day, phase 2a dose escalation study in stage 3 and 4 chronic kidney disease patients with anemia
    • Hartman C, Smith MT, Flinn C, Shalwitz I, Peters KG, Haase VH: AKB-6548, a new hypoxia-inducible factor prolyl hydroxylase inhibitor increases hemoglobin while decreasing ferritin in a 28-day, phase 2a dose escalation study in stage 3 and 4 chronic kidney disease patients with anemia. J Am Soc Nephrol 2011; 22: 435A.
    • (2011) J Am Soc Nephrol , vol.22 , pp. 435A
    • Hartman, C.1    Smith, M.T.2    Flinn, C.3    Shalwitz, I.4    Peters, K.G.5    Haase, V.H.6
  • 19
    • 0009663357 scopus 로고
    • A multiple comparison procedure for comparing several treatments with a control
    • Dunnett CW: A multiple comparison procedure for comparing several treatments with a control. J Am Stat Assoc 1955; 50: 1096-1121.
    • (1955) J Am Stat Assoc , vol.50 , pp. 1096-1121
    • Dunnett, C.W.1
  • 20
    • 84958920828 scopus 로고    scopus 로고
    • HIF prolyl hydroxylase inhibitors for the treatment of renal anaemia and beyond
    • Maxwell PH, Eckardt KU: HIF prolyl hydroxylase inhibitors for the treatment of renal anaemia and beyond. Nat Rev Nephrol 2016; 12: 157-168.
    • (2016) Nat Rev Nephrol , vol.12 , pp. 157-168
    • Maxwell, P.H.1    Eckardt, K.U.2
  • 21
    • 33947514823 scopus 로고    scopus 로고
    • Heights and haematology: The story of haemoglobin at altitude
    • Windsor JS, Rodway GW: Heights and haematology: the story of haemoglobin at altitude. Postgrad Med J 2007; 83: 148-151.
    • (2007) Postgrad Med J , vol.83 , pp. 148-151
    • Windsor, J.S.1    Rodway, G.W.2
  • 23
    • 84994143390 scopus 로고    scopus 로고
    • Vadadustat, a novel oral HIF stabilizer, provides effective anemia treatment in nondialysis-dependent chronic kidney disease
    • Pergola PE, Spinowitz BS, Hartman CS, Maroni BJ, Haase VH: Vadadustat, a novel oral HIF stabilizer, provides effective anemia treatment in nondialysis-dependent chronic kidney disease. Kidney Int 2016; 90: 1115-1122.
    • (2016) Kidney Int , vol.90 , pp. 1115-1122
    • Pergola, P.E.1    Spinowitz, B.S.2    Hartman, C.S.3    Maroni, B.J.4    Haase, V.H.5
  • 24
    • 84866940088 scopus 로고    scopus 로고
    • The role of hypoxia-inducible factor 1 in atherosclerosis
    • Gao L, Chen Q, Zhou X, Fan L: The role of hypoxia-inducible factor 1 in atherosclerosis. J Clin Pathol 2012; 65: 872-876.
    • (2012) J Clin Pathol , vol.65 , pp. 872-876
    • Gao, L.1    Chen, Q.2    Zhou, X.3    Fan, L.4
  • 26
    • 84895816264 scopus 로고    scopus 로고
    • Loss of von Hippel-Lindau protein (VHL) increases systemic cholesterol levels through targeting hypoxia-inducible factor 2α and regulation of bile acid homeostasis
    • Ramakrishnan SK, Taylor M, Qu A, Ahn SH, Suresh MV, Raghavendran K, Gonzalez FJ, Shah YM: Loss of von Hippel-Lindau protein (VHL) increases systemic cholesterol levels through targeting hypoxia-inducible factor 2α and regulation of bile acid homeostasis. Mol Cell Biol 2014; 34: 1208-1220.
    • (2014) Mol Cell Biol , vol.34 , pp. 1208-1220
    • Ramakrishnan, S.K.1    Taylor, M.2    Qu, A.3    Ahn, S.H.4    Suresh, M.V.5    Raghavendran, K.6    Gonzalez, F.J.7    Shah, Y.M.8
  • 28
    • 85019785700 scopus 로고    scopus 로고
    • Vadadustat Maintains Hemoglobin (Hb) Levels in Dialysis-Dependent Chronic Kidney Disease (DD-CKD) Patients Independent of Systemic Inflammation or Prior Dose of Erythropoiesis-Stimulating Agent (ESA): Kidney Week
    • TH-PO960
    • Haase VH, Chertow G, Block G, Pergola P, Zuraw Q, Khawaja Z, Sharma A, Maroni BJ, McCullough PA: Vadadustat Maintains Hemoglobin (Hb) Levels in Dialysis-Dependent Chronic Kidney Disease (DD-CKD) Patients Independent of Systemic Inflammation or Prior Dose of Erythropoiesis-Stimulating Agent (ESA): Kidney Week. Chicago, American Society of Nephrology, 2016, TH-PO960. http://www.akebia.com/wp-content/themes/akebia/img/media-kit/abstracts-posterspresentations/20161117%20Ph2%200011%20 ASN%202016-FINAL-v4-09Nov16.pdf.
    • (2016) Chicago, American Society of Nephrology
    • Haase, V.H.1    Chertow, G.2    Block, G.3    Pergola, P.4    Zuraw, Q.5    Khawaja, Z.6    Sharma, A.7    Maroni, B.J.8    McCullough, P.A.9
  • 29
    • 85019794376 scopus 로고    scopus 로고
    • Phase 2 study of AKB-6548, a novel hypoxia-inducible factor prolyl-hydroxylase inhibitor (HIF-PHI) in patients with end stage renal disease (ESRD) undergoing hemodialysis (HD)
    • INFO25
    • Hartman CS, Farmer TM, Annis K, Kazazi F, Pollack P, Shalwitz R: Phase 2 Study of AKB-6548, A Novel Hypoxia-Inducible Factor Prolyl-Hydroxylase Inhibitor (HIF-PHI) in Patients with End Stage Renal Disease (ESRD) Undergoing Hemodialysis (HD). Philadelphia, Kidney Week, 2014, INFO25. http://akebia.com/wp-content/themes/akebia/img/media-kit/abstracts-posters-presentations/20141106-Akebia-ASN-Informational-Poster-FINAL.pdf.
    • (2014) Philadelphia, Kidney Week
    • Hartman, C.S.1    Farmer, T.M.2    Annis, K.3    Kazazi, F.4    Pollack, P.5    Shalwitz, R.6
  • 31
    • 85019811922 scopus 로고    scopus 로고
    • Vadadustat, a novel, oral treatment for anemia of CKD, maintains stable hemoglobin levels in dialysis patients converting from erythropoiesis-stimulating agents: National kidney foundation spring clinical meeting
    • abstr 171
    • Haase VH, Hartman CS, Maroni B, Farzaneh-far R, McCullough PA: Vadadustat, A Novel, Oral Treatment for Anemia of CKD, Maintains Stable Hemoglobin Levels in Dialysis Patients Converting from Erythropoiesis-Stimulating Agents: National Kidney Foundation Spring Clinical Meeting. Boston, The National Kidney Foundation, 2016, abstr 171. http://akebia.com/wp-content/themes/akebia/img/media-kit/abstracts-posterspresentations/Akebia-NKF 2016 Poster-FINAL.pdf.
    • (2016) Boston, the National Kidney Foundation
    • Haase, V.H.1    Hartman, C.S.2    Maroni, B.3    Farzaneh-Far, R.4    McCullough, P.A.5
  • 32
    • 85019806112 scopus 로고    scopus 로고
    • Dose exposure relationship of vadadustat is independent of the level of renal function
    • Buch A, Maroni B, Hartman C: Dose exposure relationship of vadadustat is independent of the level of renal function. J Am Soc Nephrol 2015; 26: 747A.
    • (2015) J Am Soc Nephrol , vol.26 , pp. 747A
    • Buch, A.1    Maroni, B.2    Hartman, C.3
  • 34
    • 85019823036 scopus 로고    scopus 로고
    • Hemodialysis has minimal impact on the pharmacokinetics of AKB-6548, a once-daily oral inhibitor of hypoxia-inducible factor prolyl-hydroxylases (HIF-PHs) for the treatment of anemia related to chronic kidney disease (CKD)
    • Philadelphia, PA; FR-PO952. (accessed December 12, 2016)
    • Buch A, Farmer TM, Hartman C, Alcorn H, Shalwitz R: Hemodialysis has minimal impact on the pharmacokinetics of AKB-6548, a once-daily oral inhibitor of hypoxia-inducible factor prolyl-hydroxylases (HIF-PHs) for the treatment of anemia related to chronic kidney disease (CKD). In: ASN Kidney Week. Philadelphia, PA; 2014, FR-PO952. http://akebia.com/wp-content/themes/akebia/img/media-kit/abstracts-posterspresentations/20141106-Akebia-ASN-PK-Poster-FINAL.pdf. (accessed December 12, 2016).
    • (2014) ASN Kidney Week
    • Buch, A.1    Farmer, T.M.2    Hartman, C.3    Alcorn, H.4    Shalwitz, R.5


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.